The FDA approved a new use for a drug to reduce the risk of serious heart problems in adults with cardiovascular disease and either obesity or overweight.| U.S. Food and Drug Administration
In this piece, we discuss Medicare coverage of obesity treatments, the potential cost implications if Medicare covers anti-obesity drugs, and how the Inflation Reduction Act could potentially address these cost concerns.| KFF
This analysis of survey data finds that over 40% of adults under 65 with private insurance could be indicated for a GLP-1 drug though relatively few have a claim, suggesting that a much smaller share seeks treatment through healthcare providers.| Peterson-KFF Health System Tracker
Drugs solely approved to treat obesity have minimal to no coverage on most ACA Marketplace plans. Wegovy, a semaglutide approved for weight loss, is included in just 1% of Marketplace plans, while Ozempic, which has the same active ingredient but is approved for diabetes treatment and sometimes used off-label for weight loss, is included in 82% of Marketplace plan formularies. Among ACA Marketplace plans with these drugs on formulary, prior authorization is required by most plans. All plans ...| Peterson-KFF Health System Tracker
Prices for semaglutide and tirzepatide drugs are higher in the U.S. than in other countries. The U.S. has by far the highest rates of adults with obesity.| Peterson-KFF Health System Tracker
